AI assistant
H. Lundbeck A Director's Dealing 2025
3367_rns_2025-12-08_adf04a7e-55a7-4bc4-83bd-2133dda8859a.pdf
Director's Dealing
Open in viewerOpens in your device viewer
{0}------------------------------------------------
CORPORATE RELEASE
Valby, Denmark, December 8, 2025
Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||
|---|---|---|---|
| a) | Name | Barendina (Dianne) Hol | |
| 2. | Reason for the notification | ||
| a) | Position/status | Executive Vice President, People & Culture | |
| b) | Initial notification/Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant,auction platform, auctioneer or auction monitor | ||
| a) | Name | H. Lundbeck A/S | |
| b) | LEI code | 5493006R4KC2OI5D3470 | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) eachtype of transaction; (iii) each date; and (iv) each place where transactions have beenconducted | ||
| a) | Description of the financialinstrument, type of instrument | SharesB-shares: DK0061804770 | |
| Identification code | |||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 44.82 | 53,000 | ||
| d) | Aggregated information- Aggregated volume- Price | ||
| e) | Date of the transaction | 2025-12-05 | |
| f) | Place of the transaction | NASDAQ Copenhagen XCSE |
{1}------------------------------------------------
Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.
Closely associated persons/entities mean inter alia:
- spouse or cohabitant
- dependent children
- legal entities in which the executive has a controlling influence.
Contacts
Jens Høyer Anders Crillesen JSH[email protected] [email protected]
Vice President, Head of Investor Relations Head of Media Relations, Corp. Communication +45 30 83 45 01 +45 29 79 12 86
About H. Lundbeck A/S
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us via LinkedIn.